New pill targets Hard-to-Treat cancers with KRAS and BRAF mutations
Disease control
Recruiting now
This early-phase study tests an oral drug called S241656 in adults with advanced cancers that have specific genetic changes (KRAS, BRAF, or other RAS/MAPK mutations). The drug is given alone or with other cancer treatments. The goal is to find safe doses and see if the drug shrin…
Phase: PHASE1, PHASE2 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Apr 28, 2026 13:02 UTC